NexMed Announces 2010 Second Quarter Financial Results Conference Call
NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business
and seeking to leverage its proprietary, multi-route NexACT
delivery technology and internal pipeline through out-licensing
NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT ® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced today that management will hold a conference call to discuss 2010 second quarter financial results and ongoing corporate activities, on Friday, August 13, 2010 at 12:00 p.m. ET. The Company will file its Form 10-Q by the end of business on Thursday, August 12, 2010. The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of the U.S. by dialing (201) 689-8031 and asking the conference operator for the NexMed Conference Call. The teleconference replay will be available for one week by dialing in the U.S. (877) 660-6853 and outside of the U.S. by dialing (201) 612-7415. Replay pass codes 286 and 355405 are both required for playback. The conference call will also be Webcast live at http://www.investorcalendar.com/IC/CEPage.asp?ID=161064. The Webcast replay will be available for three months. About NexMed Backed by a solid, revenue generating CRO business, including a stable of over 300 clients and extensive research and development capabilities, NexMed has leveraged the flexibility of its proven NexACT ® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth will be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.